Skip to main content

Advertisement

SpringerLink
Log in

Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Objective

The present health economic analysis investigated the cost-effectiveness-ratios of either (1) rituximab or (2) an alternative TNF-alpha-inhibiting agent as second line biological treatment in patients with active rheumatoid arthritis (RA) and an inadequate response to etanercept therapy.

Methods

Incremental cost per quality-adjusted life-year (QALY) gained by rituximab treatment of RA is compared to TNF-inhibitor change (standard sequence) in a Markov-model (perspective: health care payer, full life-time approach). Direct cost components taken into account were treatment costs (medication-, administration- and monitoring costs) and resource utilisation (outpatient costs, inpatient costs). Indirect costs were estimated separately by the assessment of impaired work capacity due to RA (2008 Euro currency, discount rate 3.5%). Utility measures for the different treatment options were obtained from the ACR-response rates of published pivotal clinical trials.

Results

Direct costs amount to € 178,373 (standard sequence) and € 192,295 (rituximab sequence), respectively, rendering incremental direct costs of € 13,922. Incremental utilities yield 0.57 QALYs and the incremental cost-effectiveness-ratio (ICER) of rituximab compared to the standard sequence amounts to € 24,517. Inclusion of indirect costs leads to less incremental costs and a lower ICER of € 15,565/QALY. Thus, ICERs stay beneath the accepted threshold of € 50,000/QALY.

Conclusion

Rituximab appears to be a cost-effective treatment alternative compared to the switch between TNF-inhibitors as second line biological treatment in patients with active RA having failed etanercept.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Smolen, J., Aletaha, D.: The burden of rheumatoid arthritis and access to treatment: a medical overview. Eur. J. Health Econ. 8(Suppl 2), S39–S47 (2008)

    Article  Google Scholar 

  2. Kobelt, G., Jönsson, B.: The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur. J. Health Econ. 8(Suppl 2), 95–106 (2008)

    Article  Google Scholar 

  3. Kobelt, G., Woronoff, A.S., Richard, B., Peeters, P., Sany, J.: Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR study. Joint Bone Spine 75(4), 408–415 (2008)

    Article  Google Scholar 

  4. Pincus, T., Kavanaugh, A., Sokka, T.: Benefit/risk of therapies for rheumatoid arthritis: underestimation of the “side effects” or risks of RA leads to underestimation of the benefit/risk of therapies. Clin. Exp. Rheumatol. 22(suppl 35), S2–S11 (2004)

    Google Scholar 

  5. Kavanaugh, A., Cohen, S., Cush, J.: The evolving use of tumour necrosis factor inhibitors in rheumatoid arthritis. J. Rheumatol. 31, 1881–1884 (2004)

    Google Scholar 

  6. Kavanaugh, A.: Economic consequences of established rheumatoid arthritis and its treatment. Best Pract. Res. Clin. Rheumatol. 21, 929–942 (2007)

    Article  Google Scholar 

  7. Wong, J.: Cost-effectiveness of anti-tumor necrosis factor agents. Clin. Exp. Rheumatol. 22(suppl 35), S65–S70 (2004)

    Google Scholar 

  8. Solomon, D., Maetzel, A.: Pharmacoeconomics of prescribing for rheumatoid arthritis. Int. J. Adv. Rheumatol. 2, 91–96 (2004)

    Google Scholar 

  9. Edwards, J.C., Szczepanski, L., Szechinski, J., Filipowicz-Sosnowska, A., Emery, P., Close, D.R., et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New Engl. J. Med. 350, 2572–2581 (2004)

    Article  Google Scholar 

  10. Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54, 1390–1400 (2006)

    Article  Google Scholar 

  11. Cohen, S.B., Emery, P., Greenwald, M.W., Dougados, M., Furie, R.A., Genovese, M.C., et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793–2806 (2006)

    Article  Google Scholar 

  12. Manger, B., Michels, H., Nüsslein, H.G., Schneider, M., Sieper, J.: Komission Pharmakotherapie der deutschen Gesellschaft für Rheumatologie. Neufassung der Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur Therapie mit Tumornekrosefaktor-hemmenden Wirkstoffen bei entzündlich-rheumatischen Erkrankungen (03/2006)

  13. Kielhorn, A., Porter, D., Diamantopulos, A., Lewis, G.: Cost-utility analysis for the UK of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic DMARD. Curr. Med. Res. Opin. 24, 2639–2650 (2008)

    Article  Google Scholar 

  14. Sculpher, M., Claxton, K., Brazier, J., Jönsson, B.: Nice guidelines for economic evaluation: methodological developments and remaining uncertainties. European conference on health economics 2004, London

  15. Data on file reported to Roche by Zink A et al. 2004

  16. Keystone, E., Fleischmann, R., Emery, P., Chubick, A., Duogados, M., Baldassare, A.R., et al.: Repeated treatment courses of rituximab in rheumatoid arthritis: sustained efficacy in patients with an inadequate response to one or more TNF inhibitors. Ann. Rheum. Dis. 66(Suppl II), 432 (2007)

    Google Scholar 

  17. Emery, P., Furst, D.E., Ferraccioli, G., Udell, J., van Vollenhoven, R.F., Rowe, K., et al.: Sustained efficacy of repeat treatment courses of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs. Ann. Rheum. Dis. 66(Suppl II), 430 (2007)

    Google Scholar 

  18. Lajas, C., Abasolo, L., Bellajdel, B., Hernandez-Garcia, C., Carmona, L., Vargas, E., et al.: Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 49, 64–70 (2003)

    Article  Google Scholar 

  19. Michaud, K., Messer, J., Choi, H.K., Wolfe, F.: Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7, 527 patients. Arthritis Rheum. 48, 2750–2762 (2003)

    Article  Google Scholar 

  20. Pugner, K.M., Scott, D.I., Holmes, J.W., Hieke, K.: The costs of rheumatoid arthritis: an international long-term view. Semin. Arthritis Rheum. 29, 305–320 (2000)

    Article  Google Scholar 

  21. Yelin, E., Wanke, L.A.: An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 42, 1209–1218 (1999)

    Article  Google Scholar 

  22. Weinblatt, M.E., Kremer, J.M., Bankhurst, A.D., Bulpitt, K.J., Fleischmann, R.M., Fox, R.I., Jackson, C.G. et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor-FC fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New Engl. J. Med. 340; 253–259 (1999)

    Google Scholar 

  23. Keystone, E.C., Kavanaugh, A.F., Sharp, J.T., Tannenbaum, H., Hua, Y., Teoh, L.S., et al.: Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum. 50, 1400–1411 (2004)

    Article  Google Scholar 

  24. Genovese, M.C., Becker, J.C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., Li, T., Aranda, T., Hagerty, D.T., Dougados, M.: Abatacept for rheumatoid arthritis refractory to tumour necrosis factor alpha inhibition. New Engl. J. Med. 353, 1114–1123 (2005)

    Article  Google Scholar 

  25. Maini, R., St Clair, E.W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., et al.: Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354, 1932–1939 (1999)

    Article  Google Scholar 

  26. Bansback, N., Brennan, A., Ghatnekar, O.: Cost-effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann. Rheum. Dis. 64, 995–1002 (2005)

    Article  Google Scholar 

  27. Scott, D.L., Garood, T.: Quality of life measures: use and abuse. Baillieres Clin. Rheumatol. 14, 663–687 (2000)

    Article  Google Scholar 

  28. Briggs, A.H., O′Brien, B.J., Blackhouse, G.: Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu. Rev. Public. Health 23, 377–401 (2002)

    Article  Google Scholar 

  29. O′Brien, B.J., Briggs, A.H.: Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat. Methods Med. Res. 11, 455–468 (2002)

    Article  Google Scholar 

  30. Finckh, A., Ciurea, A., Brulhart, L., Kyburz, D., Moller, B., Dehler, S., et al.: B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 56, 1417–1423 (2007)

    Article  Google Scholar 

  31. Lindgren, P., Geborek, P., Kobelt, G.: Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from southern Sweden. Int. J. Technol. Assess. Health Care 25, 181–189 (2009)

    Article  Google Scholar 

  32. Russell, A., Beresniak, A., Bessette, L., Haraoui, B., Rahman, P., Thorne, C., Maclean, R., Dupont, D.: Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin. Rheumatol. 28, 403–412 (2009)

    Article  Google Scholar 

  33. Brennan, A., Bansback, N., Nixon, R., Madan, J., Harrison, M., Watson, K., Symmons, D.: Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology 46, 1345–1354 (2007)

    Article  Google Scholar 

  34. Vera-Llonch, M., Massarotti, E., Wolfe, F., Shadick, N., Westhovens, R., Sofrygin, O., Maclean, R., Li, T., Oster, G.: Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumour necrosis factor-alpha antagonists. J. Rheumatol. 35, 1745–1753 (2008)

    Google Scholar 

  35. Glenny, A., Altman, D., Song, F., Sakarovitch, C., Deeks, J., D’Amico, R. et al.: Indirect comparisons of competing interventions. Health Technol. Assess. 2005;9(26)

  36. Wong, J.B., Singh, G., Kavanaugh, A.: Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am. J. Med. 113, 400–408 (2002)

    Article  Google Scholar 

  37. Kobelt, G., Jönsson, L., Young, A., Eberhardt, K.: The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 42, 326–335 (2003)

    Article  Google Scholar 

  38. Hurst, S., Platen, E., Rachev, S.: Subordinated market index models: a comparison. In: Miura R (ed) Asia-Pacific financial markets, vol 4(2). Springer, Berlin, pp. 97–124

  39. Kobelt, G., Eberhardt, K., Jönsson, L., Jönsson, B.: Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 42(2):347–356 (1999)

    Article  Google Scholar 

Download references

Acknowledgments

Conflict of interest statement

There are no competing interests to be declared by the authors.

Author information

Authors and Affiliations

  1. Division of Clinical Immunology and Rheumatology, Working Group for Health Economics and Clinical Epidemiology, Hannover Medical School, Carl-Neuberg-Strasse 1, OE 6830, 30625, Hannover, Germany

    Sonja Merkesdal & Timm Kirchhoff

  2. Roche Pharma, Grenzach-Wyhlen, Germany

    Diane Wolka & Gunter Ladinek

  3. Hoffmann- La Roche, Basel, Switzerland

    Adrian Kielhorn

  4. Division of Internal Medicine I, University Köln, Cologne, Germany

    Andrea Rubbert-Roth

Authors
  1. Sonja Merkesdal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timm Kirchhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diane Wolka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gunter Ladinek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Adrian Kielhorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrea Rubbert-Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonja Merkesdal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Merkesdal, S., Kirchhoff, T., Wolka, D. et al. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. Eur J Health Econ 11, 95–104 (2010). https://doi.org/10.1007/s10198-009-0205-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-009-0205-y

Keywords

JEL Classification

Search

Navigation